LEADER 03963nam  2200709Ia 450 
001 9910972731903321
005 20251006140348.0
010   $a9786612412561
010   $a9781282412569
010   $a1282412566
010   $a9780309136914
010   $a0309136911
035   $a(CKB)2420000000001441
035   $a(EBL)3378544
035   $a(SSID)ssj0000439079
035   $a(PQKBManifestationID)11311299
035   $a(PQKBTitleCode)TC0000439079
035   $a(PQKBWorkID)10460128
035   $a(PQKB)11441070
035   $a(MiAaPQ)EBC3378544
035   $a(Au-PeEL)EBL3378544
035   $a(CaPaEBR)ebr10347048
035   $a(CaONFJC)MIL241256
035   $a(OCoLC)923280232
035   $a(Perlego)4736026
035   $a(BIP)27376687
035   $a(EXLCZ)992420000000001441
100   $a20090818d2009      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aLive variola virus $econsiderations for continuing research /$fCommittee on the Assessment of Future Scientific Needs for Live Variola Virus; Board on Global Health ; Ann M. Arvin and Deepali M. Patel, editors ; Institute of Medicine of the National Academies
205   $a1st ed.
210   $aWashington, D.C. $cNational Academies Press$d2009
215   $a1 online resource (170 p.)
300   $aDescription based upon print version of record.
311 08$a9780309136907 
311 08$a0309136903 
320   $aIncludes bibliographical references.
327   $a""Reviewers""; ""Preface""; ""Acknowledgments""; ""Contents""; ""Summary""; ""1 Introduction""; ""2 Overview of Smallpox and Its Surveillance and Control""; ""3 Comparative Poxvirology""; ""4 Animal Models Using Variola and Other Orthopoxviruses""; ""5 Genomic Analysis""; ""6 Development of Therapeutics""; ""7 Development of Vaccines""; ""8 Methods for Detection and Diagnosis""; ""9 Discovery Research""; ""10 Conclusions and Recommendations""; ""Appendix: Variola Strains Used to Validate Diagnostic and Detection Assays""
330   $aSmallpox was a devastating disease that decimated human populations for centuries, and its eradication in 1980 was a monumental achievement for the global health community. Since then the remaining known strains of its causative agent, variola virus, have been contained in two World Health Organization (WHO)-approved repositories.  In 1999, the World Health Assembly (WHA) debated the issue of destroying these remaining strains. Arguments were presented on the need to retain the live virus for use in additional important research, and the decision to destroy the virus was deferred until this research could be completed. In that same year, the Institute of Medicine (IOM) convened a consensus committee to explore scientific needs for the live virus.  In the ten years since the first IOM report, the scientific, political, and regulatory environments have changed. In this new climate, the IOM was once again tasked to consider scientific needs for live variola virus. The committee evaluated the scientific need for live variola virus in four areas: development of therapeutics, development of vaccines, genomic analysis, and discovery research. 
606   $aSmallpox$xResearch
606   $aSmallpox$xPrevention
606   $aSmallpox vaccine
606   $aVirology$xCultures and culture media
615  0$aSmallpox$xResearch.
615  0$aSmallpox$xPrevention.
615  0$aSmallpox vaccine.
615  0$aVirology$xCultures and culture media.
676   $a616.912
701   $aArvin$b Ann M$01803621
701   $aPatel$b Deepali$01642963
712 02$aInstitute of Medicine (U.S.).$bCommittee on the Assessment of Future Scientific Needs for Live Variola Virus.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910972731903321
996   $aLive variola virus$94351250
997   $aUNINA